Related Experiment Video
Updated: Oct 9, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumococcal otitis media and pneumococcal vaccines, a historical perspective
1Department of Molecular and Cellular Engineering, School of Medicine, The University of Pennsylvania, Philadelphia, PA 19104-6088, USA.
Insights
Pneumococcal conjugate vaccines show promise in preventing invasive pneumococcal disease in young children. Further studies are ongoing to assess their impact on otitis media prevention.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Pneumococcal otitis media, known since the 19th century, lacked effective prophylaxis until recent vaccine developments.
- Early whole-cell pneumococcal vaccines for pneumonia were superseded by polysaccharide vaccines, which proved less effective in infants.
Observation:
- Polysaccharide vaccines failed to elicit adequate antibody responses in infants and young children.
- The success of capsular polysaccharide-protein conjugate vaccines against Hemophilus influenzae type b spurred similar developments for pneumococcus.
Findings:
- Polyvalent pneumococcal polysaccharide-protein conjugate vaccines have demonstrated high efficacy in preventing invasive pneumococcal disease in infants.
- Ongoing research is evaluating the effectiveness of these conjugate vaccines in preventing otitis media.
Implications:
- Pneumococcal conjugate vaccines represent a significant advancement in pediatric infectious disease prevention.
- These vaccines hold potential to reduce the burden of pneumococcal otitis media, a common childhood illness.
Abstract:
Although pneumococcal otitis media was recognized in the 19th century, the illness stimulated little interest in prophylaxis until recently. Whole cell vaccines of killed pneumococci, developed to prevent pneumonia, were replaced by vaccines of capsular polysaccharides following demonstration of their antigenicity in adults. Failure of the latter to stimulate antibodies in infants and young children and demonstration of the efficacy of capsular polysaccharide-protein conjugate vaccines in preventing infection with Hemophilus influenzae type b has led to the development of polyvalent pneumococcal polysaccharide-protein conjugate vaccines. Preliminary studies have shown them to be highly effective in preventing invasive pneumococcal disease in the first 2 years of life, and studies of their impact on otitis media are currently in progress.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:29Pneumonia II: Pathophysiology
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: